Background
Hepatocellular carcinoma (HCC) is a highly aggressive cancer that is linked to chronically dysregulated liver inflammation. However, appropriate immune responses can control HCC progression. Here we investigated the role and underlying mechanism of toll-like receptor 3 (TLR3) in HCC.
Methods
HCC cell death, and natural killer (NK) cell activation and cytotoxicity were assessed in vitro after treatment with the TLR3 ligand poly(I:C). The effect of TLR3 on the tumor parenchyma and infiltrating immune cells was investigated in a spontaneous liver tumor mouse model and a transplanted tumor mouse model (n = 3-9 mice per group). Immunohistochemistry and quantitative polymerase chain reaction were used to analyze tumor samples from 172 HCC patients. Paired t-tests and analysis of variance tests were used to calculate P-values. The relationship between TLR3 expression and survival was determined by the Kaplan-Meier univariate survival analysis and a log-rank test. All statistical tests were two-sided.
Results

TLR3 activation increased cell death in the TLR3
+ SNU182 HCC cell line (30.5% vs 8.5%, P = .03) and promoted NK-cell activation (32.6% vs 19.4%, P < .001) and cytotoxicity (relative fourfold increase, P = .03) in vitro. In vivo, poly(I:C) treatment increased intratumoral chemokine expression, NK-cell activation and tumor infiltration, and proliferation of tumor-infiltrating T and NK cells. Proliferation of tumor parenchyma cells was decreased. Also, expression of chemokines or treatment with poly(I:C) decreased tumor growth. TLR3 expression in patient samples correlated with NK-cell activation, NK-and T-cell tumor infiltration, and inversely correlated with tumor parenchyma cell viability. TLR3 expression was also associated with longer survival in HCC patients (hazard ratio of survival = 2.1, 95% confidence interval = 1.3 to 3.4, P = .002).
Conclusions
TLR3 is an important modulator of HCC progression and is a potential target for novel immunotherapy.
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Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide (1) . Resection and transplantation are the most successful treatments for HCC; however, most patients relapse and overall survival remains poor. HCC is thought to result from persistent, nonspecific activation of the immune system within the chronically inflamed liver, causing repeated cycles of tissue damage, repair and regeneration, and eventually carcinogenesis (2, 3) . However, we have previously reported that expression of specific proinflammatory genes within the tumor microenvironment is associated with improved patient survival (4), suggesting a more complex role of the immune system in HCC. Toll-like receptor 3 (TLR3) is one of the key proinflammatory genes associated with "good prognosis" in HCC (4) . TLR3 is an endosomal receptor for double-stranded RNA and is expressed in several subsets of immune cells, including dendritic cells (5) and natural killer (NK) cells (6) . TLR3 is also expressed by fibroblasts (7), lung epithelial cells (8) , hepatocytes (9) , and several types of tumor cells, including breast cancer and melanoma cells (10, 11) . TLR3 is involved in antiviral responses and the production of type I interferons (IFNs) (12) . RNA from damaged tissues can also serve as a ligand for TLR3 (13, 14) . Synthetic TLR3 ligands, such as polyinosinic:polycytidylic acid [poly(I:C)] acts as potent immune adjuvants by enhancing dendritic cell cross-presentation and promoting CD8 + T-cell responses (15, 16) . Such ligands have thus been used to treat a range of malignancies in a variety of clinical settings (17) .
In vitro studies indicate that TLR3 activation triggers apoptosis of several tumor cell lines, including breast cancer (10) and melanoma (11) . Moreover, transfection of TLR3 into HCC cell lines renders them sensitive to poly(I:C)-induced killing (18) . TLR3-expressing NK cells can also be directly activated by poly(I:C) (6, 19) . However, the role of TLR3 in HCC remains to be evaluated in human patients. We explored the role played by TLR3 in the apoptosis of HCC cells and assessed the contribution of this receptor to NK-cell activation and cytotoxicity using HCC cell lines, two in vivo mouse models, and patient samples and survival data.
Materials and Methods
Cell Lines and Reagents
The methods by which the HCC cell lines (Hepa1-6, SNU182, SNU368, SNU387, SNU-423, SNU449, SNU475, PLC/PR5, HuH-7, HepG2, Hep3B, and SK-HEP-1) were maintained are described in detail in the Supplementary Methods (available online). Endotoxin-free poly (I:C) and polyadenylic-polyuridylic acid [poly(A:U)] were obtained from InvivoGen (San Diego, CA). We assumed the authenticity of the cell lines was verified by the source.
All the antibodies used for immunohistochemistry, flow cytometry, or NK-cell depletion were listed in Supplementary Table 1 (available online). TLR3 was knocked down using predesigned stealth select RNAi (Invitrogen) according to the manufacturer's instructions (Supplementary Methods, available online).
Patient Samples
Resected tumor samples were obtained from patients who underwent curative resection for HCC (n = 172) between 1991 and 2009 at the National Cancer Centre (Singapore), Queen Mary Hospital (Hong Kong, China), or the University Hospital of Zurich (Zurich, Switzerland). All samples were collected with written informed consent in compliance with the requirements of the local ethical committee at each institution. The patient demographics and clinical characteristics are summarized in Supplementary Table 2 (available online) (20) . RNA isolation, cDNA conversion, quantitative polymerase chain reaction (qPCR), and gene expression analysis were performed as described in the Supplementary Methods and Supplementary Table 3 (available online) . Because of the small number of women in the study population, we did not report subanalyses by sex, but analysis by major racial/ethnic group was done.
In Vivo Studies
Animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee, Biological Resource Centre, Agency for Science, Technology and Research (A*STAR), Singapore. The spontaneous liver tumor mouse model and transplanted tumor mouse model are described in the Supplementary Methods (available online).
Immunohistochemistry
Paraffin-embedded tissue sections of liver and tumor from HCC patients (n = 40) or from mice used in the above experiments were processed as previously described (4) . All the antibodies used are listed in Supplementary Table 1 (available online). A terminal deoxynucleotidyl transferase dUTP nick end labeling kit from Millipore (Billerica, MA) was used as per the manufacturer's protocol. Immunohistochemistry (IHC) images were captured with a DP20 camera attached to a CX31 microscope (Olympus, Center Valley, PA). For immunoflourescence images, an Olympus FlourView FV1000 confocal microscope was used. The number of positively stained cells in 10-12 random fields were counted at × 100 magnification using Image-Pro Analyzer version 6.2 (Media Cybernetics, Inc, Rockville, MD).
Flow Cytometry
Apoptotic HCC cells were identified by staining with Annexin V (BD Pharmingen, San Diego, CA) and Topro-3 (Invitrogen). Activation of CD56 + human NK cells was determined by assessing the protein expression of the early activation marker CD69 using antihuman CD69 antibody (eBiosciences, San Diego, CA). Immune cells were isolated from mouse liver tumors or healthy livers by digesting the tissues with Collagenase A (1 mg/mL) and DNase I (0.1 mg/mL; Roche, Indianapolis, IN) and were analyzed using antibodies listed in Supplementary Table 1 (available online). All flow cytometry analyses were done on a BD LSRII flow cytometer equipped with five lasers (BD Biosciences, San Jose, CA), and the data were processed using FlowJo version 7.5 software (Tree Star, Inc, Ashland, OR).
NK-Cell Activation and Cytotoxicity Assay
Blood samples from 15 healthy donors were obtained from the Singapore Health Science Authority blood bank following Ethics Committee approval. NK cells were isolated by negative selection using the NK-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), treated, and analyzed by using the DELFIA EuTDA-based cytotoxicity assay kit (Perkin-Elmer, Boston, MA) by following the manufacturer's instructions (Supplementary Methods, available online). IFN-γ present in supernatants from activated NK cells was measured by enzyme-linked immunosorbent assay (Biolegend, San Diego, CA) by following the manufacturer's instructions.
Statistical Analysis
Kaplan-Meier univariate survival analysis was performed using data from HCC patients and hazard ratios (HRs), 95% confidence intervals (CIs), and P-values were calculated using the log-rank (Mantel-Cox) test. Paired or unpaired t-tests, Mann-Whitney tests, or one-or two-way analysis of variance tests were also used in various experiments as indicated. A P-value less than .05 was considered statistically significant. All statistical tests were twosided. For more detailed information on the statistical analyses, see the Supplementary Methods (available online).
results
TLR3 Expression in Tumor Parenchyma and Infiltrating NK Cells in HCC Patient Samples
We previously reported that TLR3 gene expression in tumors was associated with overall survival among a cohort of 61 patients from Singapore (4). Here, we extended our previous study to include 111 additional patients from Hong Kong and Zurich. First, we performed qPCR on patient samples and confirmed that expression of TLR3 is associated with overall survival (HR of survival = 2.1, 95% CI = 1.3 to 3.4, P = .002) (Figure 1, A) . We also observed Figure 1 , available online). We next quantified TLR3 expression separately in tumor parenchyma (hepatocytes) and NK cells to determine if these two cell populations were associated with overall survival. As shown in Figure 1 , E, both TLR3-expressing cell populations were associated with overall survival in Kaplan-Meier analyses (tumor parenchyma: HR of survival = 7.3, 95% CI = 2.8 to 19.1, P < .001; tumor-infiltrating NK cells: HR of survival = 8.7, 95% CI = 3.2 to 23.4, P < .001).
Effect of TLR3 Activation on HCC Cell Death
To study the effects of endogenous expression of TLR3 in HCC, we screened 11 human HCC cell lines for TLR3 RNA expression by qPCR and identified seven-SNU182, SNU387, SNU449, SNU475, SK-HEP-1, HepG2, and Hep3B-that expressed the receptor (data not shown). Treatment of SNU182 cells, which exhibited high expression of TLR3, with increasing concentration of poly(I:C) for 24 hours at 37°C, resulted in a dose-dependent increase in cell death (no treatment vs 50 µg/mL poly(I:C): 8.5% vs 30.5%, P = .03; no treatment vs 100 µg/mL poly(I:C): 8.5% vs 30.9%, P = .03) (Figure 2 (Figure 3, B) . Activated NK cells displayed up to fourfold higher cytotoxic activity (E:T ratio = 5:1, P = .03) against SNU182 cells (Figure 3, D) . Thus, in vitro activation of TLR3 promotes NK-cell activation, secretion of IFN-γ, and cytotoxicity against HCC cells. This result is consistent with previous studies using lymphoma target cells (19) .
Effect of TLR3 Activation on Intratumoral Chemokine Expression and NK-Cell Infiltration
To investigate the effect of TLR3 activation in vivo, we treated mice that spontaneously develop liver tumors with poly(I:C) (22, 23) . In the tumors of treated mice compared with mice injected with PBS or livers from age-matched, tumor-free mice, increase in relative expression of the chemokine genes Ccl5 (HCC of tumor-bearing mice treated with poly(I:C) vs PBS = 19-fold increase, P = .01; vs livers of tumor-free mice = 189-fold increase, P = .02) and Cxcl9 (HCC of tumor-bearing mice treated with poly(I:C) vs PBS = fivefold increase, P = .04; vs livers of tumor-free mice = 12-fold increase, P = .04) was observed (Figure 4 
Effect of TLR3 Activation In Vivo on Intratumor Proliferation of T Cells and NK Cells and Viability of Tumor Parenchyma
We next characterized the functional status of TILs in poly(I:C)-treated mice. As shown in Figure 5 , A, the frequency of Ki67 The mean expression of the NK-cell effector genes perforin (Prf) and granzyme-B (Gzmb) was measured in liver tumors harvested from poly(I:C)-and PBS-treated mice using quantitative polymerase chain reaction. Graphs show means and SD. The Mann-Whitney test was used to calculate the two-sided P-values. D) Transplanted tumor growth was measured after NK cells were depleted using PK136 antibody or isotype control antibody (n = 3 per group). The graphs show the means and SD (whisker bars). A two-way analysis of variance test with Bonferroni correction was used to calculate two-sided P-values. The mean tumor area was statistically significantly different between PK136-treated and isotype controltreated mice at days 7, 10, and 14 (P = .005, <.001, and <.001, respectively). The Mann-Whitney test was used to calculate the two-sided P-value. Representative immunohistochemical images are also shown at × 200 magnification. Scale bar = 50 µm. E) Transplanted tumor growth was determined in mice treated with poly(I:C) vs PBS (n = 6 mice per group). On day 14, the mean tumor area of poly(I:C)-vs PBS-treated mice is 14.5 vs 39.5 mm 2 , P < .001. Whisker bars indicate the SD. A two-way analysis of variance test with Bonferroni correction was used to calculate the two-sided P-value. F) Relative gene expression of T (threefold increase in Cd3g) and NK (twofold increase in Nkp46) cell markers in transplanted tumors treated with poly(I:C) vs PBS (n = 6 mice per group) is shown. The graphs show the means and SD (whisker bars). An unpaired t-test was used to calculate the two-sided P-values.
Correlation Between TLR3, NK-Cell Infiltration, and Antitumor Activity in Patient Samples
In tumor tissue from HCC patients, a higher density of TLR3-expressing cells correlated with increased tumor infiltration by CD56 + NK cells (Pearson's r = 0.7, P < .001) and CD8 + T cells (Pearson's r = 0.6, P <.001) (Figure 6, A) . This is consistent with our previous finding that TLR3 RNA expression is associated with expression of chemokines able to attract NK cells and T cells (20) . Furthermore, TLR3 protein expression correlated with NK-cell activation marker IFNG expression when measured by qPCR (Pearson's r = 0.5, P = .001), and a similar, albeit weaker, correlation was observed with granzyme-B expression when measured by IHC (Pearson's r = 0.4, P = .03) (Figure 6, B) . Correlations between TLR3 and NCR3, CD8A, and IFNG (NK-and T-cell marker) were also observed at the RNA level in patient samples (n = 154-164) (Supplementary Table 4 
Discussion
In the past few decades, TLR agonists have emerged as promising drugs for the treatment of cancer (25) . Several TLR ligands have since been used to treat cancer patients either as a monotherapy or in combination with other therapies (17) . These ligands include the TLR7 ligand imiquimod for superficial basal cell carcinoma (26) and the TLR9 ligand CpG ODN for a variety of carcinomas (27) . In particular, TLR3 ligands were used to treat patients with various malignancies, including breast cancer (28) and melanoma (29) . We previously showed that TLR3 expression is associated with superior HCC patient survival (4). Here, we confirmed this finding using a larger set of patient samples and explored the underlying mechanisms of the beneficial role of TLR3 activation in HCC.
By integrating in vitro data from human cell lines with in vivo treatment of mice that developed spontaneous HCC or were injected with HCC cell line, we demonstrated that the prolonged survival associated with higher expression of TLR3 may result from three independent effects: induction of tumor parenchyma (hepatocytes) cell death; induction of intratumor expression of chemokines that attract NK cells or T cells to the tumor microenvironment; and activation of tumor-infiltrating NK cells that promote cytotoxic activity. These effects were consistent with transcriptomal and histopathological analyses of HCC patient samples.
TLR3 is expressed by tumor parenchyma and infiltrating NK cells. We showed that expression in both compartments correlated with reduced tumor cell proliferation, increased tumor cell death, and prolonged patient survival. TLR3 expression by tumor parenchyma was associated with improved survival even in patients with low NCR3 expression (Kaplein-Meier analysis, HR of survival = 7.1, 95% CI = 1.7 to 30.5, P = .008) (unpublished data), indicating that TLR3 expression has independent effects on the tumor parenchyma and infiltrating NK cells. Moreover, during disease progression (from stages I and II to stages III and IV), TLR3 expression is downregulated in both compartments, suggesting that expression of TLR3 in both cell populations impacts on patient survival. These findings are consistent with our in vitro data; TLR3 activation induces apoptosis and chemokine expression in tumor and also stimulates the functional activation of NK cells. Patients with high TLR3 expression are found in both early and late stage groups (P = .56) (unpublished data), suggesting that earlier diagnosis of HCC in these patients is unlikely to explain their prolonged survival.
In vitro activation of TLR3 was previously reported to trigger apoptosis in several tumor cell lines, including breast cancer (10), melanoma (11) , and even HCC cell lines transfected with TLR3 (18, 30) . TLR3 + NK cells are directly activated by treatment with poly(I:C) (6, 19, 31) . Previous studies from prostate and glioma tumor models showed that TLR3 activation enhanced chemokine expression and immune effector cell infiltration. Both studies suggest that TLR3-induced immune infiltration promotes antitumor activity. Our study confirms and expands on these previous reports by providing in vitro and in vivo evidence on the multiple mechanisms of TLR3-mediated HCC progression. The effects of TLR3 activation observed in our study are consistent with a previous study in breast cancer showing that only patients with TLR3 + tumors benefited from poly(A:U) treatment (28) .
We showed that TLR3 activation enhances intratumor expression of chemokines that attract NK cells and stimulates IFN-γ production by NK cells. IFN-γ is known to synergize with inflammatory cytokines, such as TNF-α, to further induce expression of NK cell-attracting chemokines (20, 32) . This synergy could lead to further tumor infiltration by NK cells through a positive paracrine loop. In addition, HCC cells killed by NK cells may release TLR ligands that further activate NK cells to trigger more parenchyma cell death, thus amplifying antitumor activity. These putative feedback loops will require further investigation to establish whether they can account for the strong association between TLR3 expression and prolonged HCC patient survival.
In HCC patients, we observed a correlation between intratumor expression of TLR3 and the density of tumor-infiltrating CD8 + T cells, whereas treating tumor-bearing mice with poly(I:C) failed to increase T-cell infiltration in liver tumors. This discrepancy could be attributed to the analysis of murine tumors only 3 days after treatment, which could be an insufficient time period for T cells to expand and accumulate. In patients, however, sustained signaling through TLR3 may lead to increased recruitment and proliferation of T cells. In the transplanted HCC tumor model, poly(I:C) promoted tumor infiltration by both NK and T cells at day 16.
Our study has several limitations. First, the effect of poly(I:C) on tumor growth was only analyzed in a transplanted, nonorthotopic model of HCC. In the spontaneous orthotopic model, in which tumors take months to develop, we only treated the tumors with poly(I:C) for a short time. In addition, the effect of poly(I:C) on human NK cells was assessed only with cells from healthy donors, and future studies are required to show that patient NK cells are functionally identical. Finally, not all HCC cell lines undergo apoptosis after TLR3 triggering, and the molecular basis of this variation is not known.
In summary, our study shows that TLR3 expression by tumor parenchyma and infiltrating NK cells was associated with superior HCC patient survival. TLR3 is likely to act directly on tumor parenchyma cells and promote the recruitment and activation of NK cells. Several synergistic pathways involving chemokines and IFN-γ or release of TLR ligands by dying cells may reinforce these effects. These findings emphasize the need for further clinical studies aimed at evaluating the potential of TLR3 ligands to treat HCC. 
